JP2010505801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505801A5 JP2010505801A5 JP2009530916A JP2009530916A JP2010505801A5 JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5 JP 2009530916 A JP2009530916 A JP 2009530916A JP 2009530916 A JP2009530916 A JP 2009530916A JP 2010505801 A5 JP2010505801 A5 JP 2010505801A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- serotype
- den
- vaccine composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 27
- 241000725619 Dengue virus Species 0.000 claims 9
- 208000001490 Dengue Diseases 0.000 claims 3
- 206010012310 Dengue fever Diseases 0.000 claims 3
- 208000025729 dengue disease Diseases 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0608660 | 2006-10-04 | ||
| FR0608660A FR2906724B1 (fr) | 2006-10-04 | 2006-10-04 | Methode d'immunisation contre les 4 serotypes de la dengue. |
| PCT/FR2007/052054 WO2008047023A2 (fr) | 2006-10-04 | 2007-10-02 | Methode d'immunisation contre les 4 serotypes de la dengue |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010505801A JP2010505801A (ja) | 2010-02-25 |
| JP2010505801A5 true JP2010505801A5 (enExample) | 2010-10-28 |
| JP5269796B2 JP5269796B2 (ja) | 2013-08-21 |
Family
ID=38222583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530916A Expired - Fee Related JP5269796B2 (ja) | 2006-10-04 | 2007-10-02 | ４種のデング血清型に対する免疫付与の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7718358B2 (enExample) |
| EP (3) | EP2526965A1 (enExample) |
| JP (1) | JP5269796B2 (enExample) |
| KR (1) | KR20090064593A (enExample) |
| CN (2) | CN101553251B (enExample) |
| AR (1) | AR063057A1 (enExample) |
| AU (1) | AU2007311792B2 (enExample) |
| BR (1) | BRPI0719849A2 (enExample) |
| CA (1) | CA2663885A1 (enExample) |
| FR (1) | FR2906724B1 (enExample) |
| IL (2) | IL197768A0 (enExample) |
| MX (1) | MX2009003417A (enExample) |
| TW (2) | TWI406673B (enExample) |
| WO (1) | WO2008047023A2 (enExample) |
| ZA (1) | ZA200901816B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1924280A4 (en) * | 2005-08-10 | 2008-12-10 | Acambis Inc | VACCINATION AGAINST DENGUE VIRUS INFECTION |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| AU2009221180B2 (en) | 2008-03-05 | 2014-02-13 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| WO2010141386A1 (en) * | 2009-06-01 | 2010-12-09 | Inviragen, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| EP2473624B1 (en) | 2009-08-31 | 2019-05-01 | Gen-Probe Incorporated | Dengue virus assay |
| EP2353609A1 (en) * | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| US10238734B2 (en) * | 2010-03-23 | 2019-03-26 | The Regents Of The University Of California | Compositions and methods for self-adjuvanting vaccines against microbes and tumors |
| SG195115A1 (en) * | 2011-06-29 | 2013-12-30 | Immunotope Inc | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection |
| EP2858668A1 (en) * | 2012-06-10 | 2015-04-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8895028B2 (en) * | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
| JP2015524421A (ja) * | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | ワクチン組成物 |
| US20150265695A1 (en) | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
| CA2933472A1 (en) * | 2012-12-14 | 2014-06-19 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| WO2014204892A1 (en) | 2013-06-21 | 2014-12-24 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| MY192543A (en) | 2014-12-22 | 2022-08-26 | Merck Sharp & Dohme | Dengue virus vaccine compositions and methods of use thereof |
| EP3316905A1 (en) | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| TWI736563B (zh) * | 2015-11-27 | 2021-08-21 | 日商Ｋｍ生物醫藥股份有限公司 | 庫存之登革熱病毒減毒株的活病毒及以此等做為抗原之登革熱疫苗 |
| US11690903B2 (en) | 2017-10-05 | 2023-07-04 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
| KR20210071979A (ko) | 2018-09-05 | 2021-06-16 | 다케다 백신즈 인코포레이티드 | 뎅기열 백신 단위 용량 및 이의 투여 |
| KR20220049023A (ko) | 2019-08-16 | 2022-04-20 | 다케다 백신즈 인코포레이티드 | 뎅기열 및 a형 간염을 예방하기 위한 방법 |
| WO2021174059A1 (en) | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| WO2024118740A1 (en) | 2022-11-29 | 2024-06-06 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| DE69830579T2 (de) | 1997-02-28 | 2006-05-04 | Acambis, Inc., Cambridge | Chimäre impfstoffe gegen flaviviren |
| EP1080370A4 (en) | 1998-05-29 | 2003-07-30 | Epimmune Inc | IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE |
| CA2365728A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| AU4040400A (en) * | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
| EP1165127B1 (en) * | 1999-03-26 | 2008-12-31 | Walter Reed Army Institute of Research | Multivalent dengue virus vaccine |
| US6511667B1 (en) | 1999-03-26 | 2003-01-28 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-2 virus vaccine |
| US6528065B1 (en) | 1999-03-26 | 2003-03-04 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-3 virus vaccine |
| US6632663B1 (en) | 1999-09-22 | 2003-10-14 | Aventis Pasteur Limited | DNA immunization against chlamydia infection |
| ATE526411T1 (de) | 2000-02-16 | 2011-10-15 | Us Gov Health & Human Serv | Avirulente, immunogene flavivirus-chimäre |
| ES2315221T3 (es) * | 2000-05-30 | 2009-04-01 | Mahidol University | Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea. |
| EP1159969A1 (fr) | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| ES2533085T3 (es) | 2001-05-22 | 2015-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos |
| JP2005518332A (ja) | 2001-05-23 | 2005-06-23 | デンドレオン コーポレイション | 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用 |
| AU2002322026B2 (en) | 2001-06-01 | 2008-03-13 | Acambis Inc. | Chimeric flavivirus vectors |
| US20040120964A1 (en) * | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| US7459160B2 (en) * | 2002-01-15 | 2008-12-02 | Acambis Inc. | Chimeric flaviviruses |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| CN1791433B (zh) * | 2003-03-24 | 2010-05-26 | 斯克里普斯研究学院 | 抗肿瘤生长的dna疫苗及其使用方法 |
| JP5197362B2 (ja) * | 2005-06-17 | 2013-05-15 | サノフィ・パスツール | デング熱セロタイプ１弱毒株 |
| EP1924280A4 (en) * | 2005-08-10 | 2008-12-10 | Acambis Inc | VACCINATION AGAINST DENGUE VIRUS INFECTION |
| FR2903605A1 (fr) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2006
- 2006-10-04 FR FR0608660A patent/FR2906724B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-20 TW TW096135167A patent/TWI406673B/zh not_active IP Right Cessation
- 2007-09-20 TW TW102119488A patent/TW201336508A/zh unknown
- 2007-09-28 AR ARP070104316A patent/AR063057A1/es unknown
- 2007-10-02 EP EP11192672A patent/EP2526965A1/fr not_active Withdrawn
- 2007-10-02 CA CA002663885A patent/CA2663885A1/en not_active Abandoned
- 2007-10-02 BR BRPI0719849-3A2A patent/BRPI0719849A2/pt active Search and Examination
- 2007-10-02 EP EP07858487.7A patent/EP2077857B1/fr not_active Not-in-force
- 2007-10-02 EP EP11192665A patent/EP2526964A1/fr not_active Withdrawn
- 2007-10-02 CN CN2007800444299A patent/CN101553251B/zh not_active Expired - Fee Related
- 2007-10-02 US US11/866,382 patent/US7718358B2/en not_active Expired - Fee Related
- 2007-10-02 KR KR1020097008657A patent/KR20090064593A/ko not_active Abandoned
- 2007-10-02 JP JP2009530916A patent/JP5269796B2/ja not_active Expired - Fee Related
- 2007-10-02 AU AU2007311792A patent/AU2007311792B2/en not_active Ceased
- 2007-10-02 ZA ZA200901816A patent/ZA200901816B/xx unknown
- 2007-10-02 WO PCT/FR2007/052054 patent/WO2008047023A2/fr not_active Ceased
- 2007-10-02 CN CN201310128837XA patent/CN103285386A/zh active Pending
- 2007-10-02 MX MX2009003417A patent/MX2009003417A/es active IP Right Grant
-
2009
- 2009-03-23 IL IL197768A patent/IL197768A0/en not_active IP Right Cessation
-
2010
- 2010-03-05 US US12/718,308 patent/US20100270202A1/en not_active Abandoned
-
2013
- 2013-02-04 IL IL224572A patent/IL224572A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505801A5 (enExample) | ||
| JP2010511022A5 (enExample) | ||
| WO2008047023A3 (fr) | Methode d'immunisation contre les 4 serotypes de la dengue | |
| JP2015524421A5 (enExample) | ||
| JP2007302683A5 (enExample) | ||
| IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
| WO2008022196A3 (en) | Development of dengue virus vaccine components | |
| WO2009080836A3 (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
| JP2002540168A5 (enExample) | ||
| CY1112999T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| NO20090141L (no) | Stabiliserte, farmasøytiske preparater som omfatter fesoterodin | |
| MX2021002586A (es) | Dosis unitaria de vacuna contra el dengue y administracion de esta. | |
| JP2009504654A5 (enExample) | ||
| NO20065190L (no) | Farmasoytiske sammensetninger omfattende en amfifil stivelse | |
| PH12016502431A1 (en) | Composition and methods for administration of vaccines against dengue virus | |
| WO2006083286A3 (en) | Genetically engineered swine influenza virus and uses thereof | |
| FI3250182T3 (fi) | Dispergoituvia koostumuksia | |
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| ATE419006T1 (de) | Multivalenter dengue-virus impfstoff | |
| WO2007057763A3 (en) | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant | |
| PH12013501373B1 (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| WO2006088481A3 (en) | Genetically engineered equine influenza virus and uses thereof | |
| JP2009515987A5 (enExample) | ||
| JP2018502080A5 (enExample) | ||
| WO2002078631A3 (en) | Improved conditionally replicating vectors for inhibiting viral infections |